References
- Piantadosi S. Clinical trials: A methodologic perspective (2nd edition). New York, NY: Wiley; 2005
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen HB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; https://doi.org/10.1056/NEJMoa1003466
- Topalian SL, Hodi S, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Eng J Med 2012; 366:2443-54; PMID:22658127; https://doi.org/10.1056/NEJMoa1200690
- Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-Cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; https://doi.org/10.1158/1078-0432.CCR-11-0116
- Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric Antigen Receptor-Modified T cells for Acute Lymphoid Leukemia. N Eng J Med 2013; 368:1509-18; PMID:23527958; https://doi.org/10.1056/NEJMoa1215134
- Kirsch IR, Watanabe R, O'Malley JT, Williamson DW, Scott LL, Elco CP, Teague JE, Gehad A, Lowry EL, LeBoeuf NR, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med 2015; 7 Issue 308:308ra158; PMID:26446955; https://doi.org/10.1126/scitranslmed.aaa9122
- Davis MM. Immunology taught by humans. Sci Transl Med 2012; 4:117fs2; PMID:22261029; https://doi.org/10.1126/scitranslmed.3003385
- Rahma OE, Gammoh E, Simon R, Khleif SN. Is the “3+3” dose escalation phase 1 clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for an alternative design. Cancer Res 2014; 20:4758-67.
- Hunsberger S, Rubinstein LV, Dancey J, Korn EL. Dose escalation trial designs based on a molecularly targeted endpoint. Statistics Med 2005; 24:2171-81; PMID:15909289; https://doi.org/10.1002/sim.2102
- Hoos A, Eggermont AMM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Institute 2010; 18:1388-97; https://doi.org/10.1093/jnci/djq310
- Stampfer MJ, Buring JE, Willett W, Rosner B, EberleinK , Hennekens CH. The 2 × 2 factorial design: Its application to a randomized trial of aspirin and U.S. physicians. Statistics Med 1985; 4:111-6; PMID:4023472; https://doi.org/10.1002/sim.4780040202
- Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Therapeutics 1997; 61:275-91; https://doi.org/10.1016/S0009-9236(97)90160-0
- Simon RM, Steinberg SM, Hamilton M, Hildesheim A, Khleif S, Kwak LW, Mackall CL, Schlom J, Topalian SL, Berzofsky JA. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 2001; 19:1848-54; PMID:11251017; https://doi.org/10.1200/JCO.2001.19.6.1848
- Thall PF, Simon R, Ellenberg SS. Two-stage selection and testing designs for comparative clinical trials. Biometrika 1988; 75:303-10; https://doi.org/10.1093/biomet/75.2.303
- Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 1989; 45:537-48; PMID:2765637; https://doi.org/10.2307/2531495
- Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2012; 9:199-207; https://doi.org/10.1038/nrclinonc.2011.165
- Carey LA, Winer EP. I-SPY 2: Toward more rapid progress in breast cancer treatment. N Eng J Med 2016; 375:83-4; PMID:27406352; https://doi.org/10.1056/NEJMe1603691